Vincamine

Vincamine

SCHEMBL3767

CCC12CCCN3CCc4c(n(c5ccccc45)C(O)(C(=O)OC)C1)C32

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 1.00
KCNH2 Q12809 3/20 1.00
CYP2D6 P10635 3/20 1.00
HIF1A Q16665 3/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
KDM4E B2RXH2 2/20 1.00
MAPT P10636 2/20 1.00
GAA P10253 1/20 1.00
CASP6 P55212 1/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
NR1I2 O75469 3/20 0.78
PDE4D Q08499 2/20 0.78
HRH3 Q9Y5N1 2/20 0.78
OPRK1 P41145 1/20 0.78
LMNA P02545 3/20 0.57
CYP1A2 P05177 2/20 0.57
TSHR P16473 2/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vincamine SCHEMBL14095103 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL147179 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL30892136 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL29710919 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL8970683 1.00 CYP3A4 (1.00) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL8134417 0.99 CYP3A4 (0.98) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL6631357 0.98 CYP3A4 (0.96) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL5712113 0.98 CYP3A4 (0.96) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL6162410 0.97 CYP3A4 (0.95) CYP3A4KCNH2CYP2D6HIF1AMEN1
Vincamine SCHEMBL11619815 0.97 CYP3A4 (0.93) CYP3A4KCNH2CYP2D6HIF1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 103741 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239899-A1 TCR MIMIC MONOCLONAL ANTIBODIES REACTIVE WITH THE PHOSPHO-NEOANTIGEN PIRS2/HLA-A*02:01 COMPLEX AND USES THEREOF MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2024-07-18 US claimed
US-20240239799-A1 (S)-1-(5-((PYRIDIN-3-YL)THIO)PYRAZIN-2-YL)-4'H,6'H-SPIRO[PIPERIDINE-4,5'-PYRROLO [1,2-B]PYRAZOL]-4'-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS SHP2 INHIBITORS FOR THE TREATMENT OF E.G. CANCER C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2024-07-18 US claimed
WO-2024148437-A1 USE OF PCLX-001 OR PCLX-002 AS A RADIOSENSITIZER PACYCLEX PHARMACEUTICALS INC. (CA) 2024-07-18 WO claimed
WO-2024151548-A2 PROCESS FOR PURIFICATION OF CHEMICAL COMPONENTS FROM PLANT MATTER KB CRASH CREATINS LLC (US) 2024-07-18 WO claimed
EP-3868409-B1 THIOPHENOL-MALEIMIDE AND BROM-MALEIMIDE DERIVATIVES AS LINKER FOR ANTIBODY-DRUG CONJUGATES (ADC) FOR TREATING TUMORS REMEGEN CO LTD (CN) 2024-07-17 EP claimed
CN-112912076-B Use of carbamate compounds for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy 爱思开生物制药株式会社 2024-07-16 CN claimed
CN-114786682-B Fibronectin type III domain binding CD71 ARO生物疗法公司 2024-07-16 CN claimed
CN-118354776-A Methods and compositions for enhanced efficacy and reduced toxicity of non-implanted CD8 depleted allogeneic donor lymphocyte infusions 约翰霍普金斯大学 2024-07-16 CN claimed
US-12037379-B2 CD71 binding fibronectin type III domains Aro Biotherapeutics Company (US) 2024-07-16 US claimed
CN-118355033-A Compositions and methods comprising anti-NRP 2a antibodies ATYR 医药公司 2024-07-16 CN claimed
EP-0062457-A2 Improvements in or relating to the production of chemical compounds UNITED KINGDOM ATOMIC ENERGY AUTHORITY (GB) 1982-10-13 EP claimed
US-4309415-A LINOLENIC ACID OR DERIVATIVE WITH MATERIAL WHICH ENHANCES BIOSYNTHESIS OF THROMBOXANE A2 VERRONMAY LIMITED (GB) 1982-01-05 US claimed
EP-0041030-A1 Compositions for topical use containing Ergot or Vinca Rosea alkaloids for treatment of hyperseborrhoea, and their preparation PIERRE FABRE S.A. (FR) 1981-12-02 EP claimed
EP-0037175-A1 Pharmaceutical compositions EFAMOL LIMITED (GB) 1981-10-07 EP claimed
EP-0035856-A2 Pharmaceutical and dietary compositions EFAMOL LIMITED (GB) 1981-09-16 EP claimed
US-4279817-A Method for producing dimer alkaloids THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 1981-07-21 US claimed
US-4172077-A Process for the isolation of alkaloid components from the plant Vinca Rosea L. RICHTER GEDEON VEGYESZETI GYAR RT (HU) 1979-10-23 US claimed
EP-0004770-A2 Pharmaceutical and dietary composition comprising gamma-linolenic acids EFAMOL LIMITED (GB) 1979-10-17 EP claimed
US-3965254-A Compositions for the treatment of calcific tumors THE PROCTER & GAMBLE COMPANY (US) 1976-06-22 US claimed
US-3932417-A Dimeric indole alkaloid purification process ELI LILLY AND COMPANY (US) 1976-01-13 US claimed